EUVIMEDEUVIMED entdecken
Crossref

Diagnostic performance of flow cytometric osmotic fragility testing in hereditary spherocytosis

Silvia Escribano Serrat iD, Patricia Molina, Pilar Gómez, Mireia Garre, Meritxell Nomdedeu, Blanca De Moner, Estefanía García, Ana Belén Moreno-Castaño, Álex Ramos, Julia Martinez-Sanchez, Marc Pino, Ginés Escolar und 1 weitere

Cytometry Part B: Clinical Cytometry · 12.05.2026

DOI: 10.1002/cyto.b.70040 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cytometry Part B: Clinical Cytometry, online erschienen am 12.05.2026. Verfasst von Silvia Escribano Serrat und 12 weiteren Autor:innen. Beteiligte Einrichtung: Hemostasis and Erythropathology Laboratory, Hematopathology, Department of Pathology, Biomedical Diagnostic Center (CDB), Hospital Clínic de Barcelon…. Die Arbeit nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hereditary spherocytosis (HS) is the most common congenital red blood cell membrane disorder, characterized by structural protein defects that lead to hemolytic anemia. Although several diagnostic tests exist, including osmotic fragility tests (OFTs), acidified glycerol lysis test (AGLT), and the EMA‐binding test (EMA), each presents specific limitations regarding sensitivity, specificity, or technical requirements. Flow cytometric osmotic fragility testing (OFT‐FCM) emerges as a promising complementary assay, offering a standardized workflow and rapid turnaround time. We conducted a retrospective study including 106 subjects (20 HS patients and 86 healthy controls) recruited at Hospital Clínic de Barcelona between September 2024 and September 2025. Clinical and laboratory data were collected, and all participants underwent OFT, AGLT, EMA, and OFT‐FCM using two acquisition protocols (300 and 214 s). Logistic regression and receiver operating characteristic curve analysis were performed to evaluate diagnostic performance and determine optimal cut‐off values. HS patients exhibited significantly altered hematologic parameters compared with controls, including higher reticulocyte counts, red cell distribution width, and mean corpuscular hemoglobin. The EMA‐binding test demonstrated high specificity (100%) but lower sensitivity (57.9%). OFT achieved high sensitivity (>97%) but low specificity (

Schlagwörter

Stichwörter der Autor:innen

diagnosis, osmotic fragility testflow cytometryhereditary spherocytosis

Autor:innen und Institutionen

  • Hemostasis and Erythropathology Laboratory, Hematopathology, Department of Pathology, Biomedical Diagnostic Center (CDB), Hospital Clínic de Barcelona, Barcelona, Spain.
  • Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Facultat de Medicina I Ciénces de la Salut, University of Barcelona, Barcelona, Spain.
  • Hemotherapy and Hemostasis Department, Cancer and Blood Diseases Institute, Hospital Clínic de Barcelona, Barcelona, Spain.
  • Josep Carreras Leukaemia Research Institute, Hospital Clínic de Barcelona, Barcelona, Spain.

ORCID-Profile: Silvia Escribano Serrat

Zitieren

APA

Escribano Serrat, S., Molina, P., Gómez, P., Garre, M., Nomdedeu, M., De Moner, B., García, E., Moreno-Castaño, A. B., Ramos, Á., Martinez-Sanchez, J., Pino, M., Escolar, G., & Díaz-Ricart, M. (2026). Diagnostic performance of flow cytometric osmotic fragility testing in hereditary spherocytosis. Cytometry Part B: Clinical Cytometry. https://doi.org/10.1002/cyto.b.70040

Vancouver

Escribano Serrat S, Molina P, Gómez P, Garre M, Nomdedeu M, De Moner B, et al. Diagnostic performance of flow cytometric osmotic fragility testing in hereditary spherocytosis. Cytometry Part B: Clinical Cytometry. 2026. doi:10.1002/cyto.b.70040

BibTeX
@article{EscribanoSerrat2026,
  author = {Escribano Serrat, Silvia and Molina, Patricia and Gómez, Pilar and Garre, Mireia and Nomdedeu, Meritxell and De Moner, Blanca and García, Estefanía and Moreno-Castaño, Ana Belén and Ramos, Álex and Martinez-Sanchez, Julia and Pino, Marc and Escolar, Ginés and Díaz-Ricart, Maribel},
  title = {Diagnostic performance of flow cytometric osmotic fragility testing in hereditary spherocytosis},
  journal = {Cytometry Part B: Clinical Cytometry},
  year = {2026},
  doi = {10.1002/cyto.b.70040}
}
Kostenlos starten →